Atagabalin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Atagabalin
Atagabalin structure.png
Systematic (IUPAC) name
[(3S,4S)-1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid
Clinical data
Legal status
?
Identifiers
CAS number 223445-75-8 N
ATC code None
PubChem CID 9794485
ChemSpider 7970252 YesY
UNII JT7957Q2FB YesY
ChEMBL CHEMBL593430 YesY
Chemical data
Formula C10H19NO2 
Mol. mass 185.263 g/mol
 N (what is this?)  (verify)

Atagabalin (PD-0200,390) is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2).[1] It is under development as a treatment for insomnia.[2][3][4]

See also[edit]

References[edit]

  1. ^ Blakemore DC, Bryans JS, Carnell P, Carr CL, Chessum NE, Field MJ, Kinsella N, Osborne SA, Warren AN, Williams SC (January 2010). "Synthesis and in vivo evaluation of bicyclic gababutins". Bioorganic & Medicinal Chemistry Letters 20 (2): 461–4. doi:10.1016/j.bmcl.2009.11.118. PMID 20005103. 
  2. ^ Corrigan B, Feltner DE, Ouellet D, Werth JL, Moton AE, Gibson G (August 2009). "Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit". British Journal of Clinical Pharmacology 68 (2): 174–80. doi:10.1111/j.1365-2125.2009.03444.x. PMC 2767279. PMID 19694735. 
  3. ^ Quintero JE, Pomerleau F, Huettl P, Johnson KW, Offord J, Gerhardt GA (May 2011). "Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: Basic characterization and drug pharmacology". Brain Research 1401: 1–9. doi:10.1016/j.brainres.2011.05.025. PMID 21664606. 
  4. ^ Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO (June 2011). "Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models". Pharmaceutical Research 28 (10): 2610–27. doi:10.1007/s11095-011-0490-x. PMID 21681607.